You have 9 free searches left this month | for more free features.

Ixazomib

Showing 1 - 25 of 142

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Multiple Myeloma Trial in Hangzhou (Ixazomib plus low-dose lenalidomide, Ixazomib)

Recruiting
  • Multiple Myeloma
  • Ixazomib plus low-dose lenalidomide
  • Ixazomib
  • Hangzhou, Zhejiang, China
    Yang Xu
Feb 9, 2023

Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 15, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Ann Arbor, Saint Louis (Dexamethasone, Ixazomib,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
  • +3 more
Jan 6, 2023

Kaposi Sarcoma, Skin Trial in Los Angeles, Saint Louis (Ixazomib Citrate, Quality-of-Life Assessment, Questionnaire

Suspended
  • Kaposi Sarcoma
  • Skin
  • Ixazomib Citrate
  • +2 more
  • San Diego, California
  • +1 more
Jan 30, 2023

Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)

Active, not recruiting
  • Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 10, 2023

Multiple Myeloma Trial in United States (Ixazomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Ixazomib
  • +2 more
  • Duarte, California
  • +9 more
Jan 11, 2023

Plasma Cell Myeloma, Transplant-Related Carcinoma Trial in Seattle (Ixazomib Citrate, Laboratory Biomarker Analysis,

Active, not recruiting
  • Plasma Cell Myeloma
  • Transplant-Related Carcinoma
  • Ixazomib Citrate
  • +2 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center
Jul 12, 2022

Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative Trial in Houston (Doxorubicin,

Recruiting
  • Metastatic Kidney Medullary Carcinoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 20, 2023

Mantle-Cell Lymphoma Trial in United States (Ixazomib, Ibrutinib)

Active, not recruiting
  • Mantle-Cell Lymphoma
  • Atlanta, Georgia
  • +13 more
Nov 17, 2022

Human Immunodeficiency Virus (HIV) Trial in Rochester (Ixazomib 1 MG, Ixazomib 2 MG, Ixazomib 3 MG)

Completed
  • Human Immunodeficiency Virus (HIV)
  • Ixazomib 1 MG
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic
Dec 8, 2021

Multiple Myeloma, High Risk Smoldering Multiple Myeloma Trial in United States (Ixazomib (MLN9708), Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • High Risk Smoldering Multiple Myeloma
  • Basking Ridge, New Jersey
  • +5 more
Nov 15, 2022

Multiple Myeloma Trial in Pawtucket, Providence (Ixazomib, Cyclophosphamide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Ixazomib
  • +2 more
  • Pawtucket, Rhode Island
  • +2 more
Jul 21, 2022

Mantle Cell Lymphoma Trial in Busan (Ixazomib)

Recruiting
  • Mantle Cell Lymphoma
  • Ixazomib
  • Busan, Western, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Ixazomib, Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Ixazomib
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Apr 13, 2022

Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Smoldering Multiple Myeloma
  • Ixazomib
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 15, 2022

AML, AML, Adult Trial in Indianapolis (TAK-659, Ixazomib)

Terminated
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
Mar 15, 2022

Plasma Cell Myeloma Trial in Rochester (biological, drug, other)

Active, not recruiting
  • Plasma Cell Myeloma
  • Daratumumab
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic
Sep 8, 2022

Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Ixazomib (NINLARO®) capsules / Matching placebo capsules
  • London, Greater London, United Kingdom
    Royal London Hospital, Barts Health NHS Foundation Trust
Feb 17, 2022

Myeloma Trial in La Jolla, Orange, Sacramento (Clarithromycin, Dexamethasone, Ixazomib Citrate)

Active, not recruiting
  • Myeloma
  • La Jolla, California
  • +2 more
Mar 14, 2022

Relapsed/Refractory Multiple Myeloma Trial in La Jolla (Ixazomib, Pomalidomide, Dexamethasone)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Ixazomib
  • +3 more
  • La Jolla, California
    UCSD Moores Cancer Center
Mar 7, 2022

Plasmacytoma, POEMS Syndrome Trial in Rochester (Dexamethasone, Ixazomib Citrate, Lenalidomide)

Active, not recruiting
  • Plasmacytoma
  • POEMS Syndrome
  • Rochester, Minnesota
    Mayo Clinic in Rochester
May 26, 2022

Hematopoietic Stem Cell Transplantation, Multiple Myeloma Trial in Spain (Ixazomib, Tacrolimus, Sirolimus)

Recruiting
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma
  • Ixazomib
  • +3 more
  • Badalona, Spain
  • +7 more
May 20, 2022

Multiple Myeloma Trial in Beijing (Ixazomib, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Beijing, Beijing, China
    PekingUMCH
Nov 30, 2021

Recurrent Plasma Cell Myeloma Trial in Rochester (drug, other, biological)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Rochester, Minnesota
    Mayo Clinic in Rochester
May 19, 2022

Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis Trial in Scottsdale (Ixazomib)

Recruiting
  • Systemic Sclerosis
  • +18 more
  • Ixazomib
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
May 3, 2022